Intec Pharma Ltd (NASDAQ, TASE: NTEC), a clinical-stage biopharmaceutical company, has collaborated with LTS Lohmann Therapie-Systeme AG, a company that develops and manufactures transdermal drug delivery systems for pharmaceutical active substances.
It was reported yesterday that the collaboration is aimed at manufacturing Intec's lead product candidate, Accordion Pill Carbidopa/Levodopa intended for the treatment of the severe symptoms in advanced Parkinson's Disease patients.
According to the contract, LTS Lohmann Therapie-Systeme AG will produce the AP-CD/LD capsules using Intec's proprietary Accordion Pill production technology in LTS' manufacturing facility in Andernach, Germany, upon the completion of assembly of the production line. Presently, Intec is producing the AP-CD/LD capsules for its Phase three clinical trial at its present manufacturing facility in Jerusalem and will work together with LTS to establish commercial scale production capabilities for AP-CD/LD capsules.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval